ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

actinium AC-225 vipivotide tetraxetan

In Novartis’s pipeline, Radioligand therapy target PSMA. Its studies are mostly in Prostatic Neoplasms, led by Novartis.

Furthest: phase 3, since Dec 17, 20242 company-led studies, 2 open or runningNext primary completion: Jun 27, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis22 open or runningphase 3since Dec 17, 2024Dec 17, 2024Jun 27, 2028phase 3 · NCT06780670
  • Named in Novartis’s own pipeline as AAA817 (225Ac-PSMA-617), phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 17, 2024First study: phase 3 study in Prostatic NeoplasmsFirst studyNCT06780670 · 443 planned · United States, Australia, Brazil and more
  2. Feb 18, 2025Phase 3 study in Prostatic NeoplasmsNCT06855277 · 940 planned · United States, Australia, Brazil and more

Ahead

  1. Jun 27, 2028Primary completion: phase 3 study in Prostatic NeoplasmsNCT06780670
  2. Sep 29, 2028Primary completion: phase 3 study in Prostatic NeoplasmsNCT06855277

TargetBeta

“Radioligand therapy target PSMA”the company's pipeline, read by Claude · source

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
flotufolastat F 18ruleBraccophase 47
piflufolastatruleLantheusphase 45
abefolastat tesaroxetan CU-64ruleclarity-pharmaceuticals-ltdphase 35
gallium 68 PSMA-11ruleNovartisphase 34
Lutetium Lu 177 Ludotadipeprulefuturechemphase 33
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 32
HRS-4357Jiangsu HengRui Medicinephase 32
zadavotide guraxetanAstraZenecaphase 24
AB-001rulefrontier-biotechnologies-incphase 23
olsutamigruleRegeneron Pharmaceuticalsphase 22
SHR-4394Jiangsu HengRui Medicinephase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06855277Prostatic Neoplasms · United States, Australia, Brazil and more3RecruitingSep 29, 2028940
NCT06780670Prostatic Neoplasms · United States, Australia, Brazil and more3RecruitingJun 27, 2028443

How it is read

Names in the registry

  • “AAA817”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.